We can’t escape our AI future

This is the Theme of the Week edition of Bloomberg Opinion Today, a digest of our top commentary published every Sunday. Follow us on Instag [Bloomberg]( This is the Theme of the Week edition of [Bloomberg Opinion Today](, a digest of our top commentary published every Sunday. Follow us on [Instagram](, [TikTok](, [Twitter](, [Threads]( and [Facebook](. I’m about to go on vacation, and honestly, after a busy and somewhat stressful summer, my brain is ready to check out for a couple of weeks. I was sorely tempted to ask ChatGPT to write this newsletter for me; while that didn’t pan out, it does feel like a good time for a roundup of our most recent columns on AI. Here’s what Bloomberg Opinion’s AI mavens had to say about the state of our future in tech. [AI Won’t Supercharge the US Economy]( — Tyler Cowen [There’s Too Much Money Going to AI Doomers]( — Parmy Olson [Do Oppenheimer’s Warnings About Nuclear Weapons Apply to AI?]( — Hal Brands [Worried About Rogue Chatbots? Hire a Hacker]( — Dave Lee [CEOs Must Soldier On Even as AI Anxieties Loom]( — Adrian Wooldridge [Meet the New Bonds, Same as the Old Bonds]( — John Authers and Isabelle Lee [Foxconn Isn’t Letting a Good Downturn Go to Waste]( — Tim Culpan [Amazon’s Departing Alexa Boss Never Found the Reason ‘Why’]( — Dave Lee What We’re Watching At long last, we have a new treatment option for people with Alzheimer’s: The FDA recently approved a new drug that has been shown to slow the progression of the disease. Few Alzheimer’s treatments have been approved by the FDA, and Leqembi is only the second to address its progression. But researchers have found a way to repurpose over 40 years of data examining a different disease to better understand Alzheimer’s and other forms of dementia. Bloomberg columnist Lisa Jarvis breaks down [this innovative approach]( to understanding this devastating disease. Follow Us You received this message because you are subscribed to Bloomberg's Opinion Today newsletter. If a friend forwarded you this message, [sign up here]( to get it in your inbox. [Unsubscribe]( [Bloomberg.com]( [Contact Us]( Bloomberg L.P. 731 Lexington Avenue, New York, NY 10022 [Ads Powered By Liveintent]( [Ad Choices](